fbpx
01 / 05
Chlamydia Vaccine Shows Promise in Early Trial

NBC News | Vaccination

Chlamydia Vaccine Shows Promise in Early Trial

“An early-stage clinical trial yielded promising results for a chlamydia vaccine, researchers reported Thursday in The Lancet Infectious Diseases. 

There is currently no vaccine to protect against the sexually transmitted infection, which is the most common bacterial STI in the United States…

The phase 1 clinical trial, led by researchers in the United Kingdom and Denmark, found that the experimental vaccine was safe and induced an immune response.”

From NBC News.

Gavi | Vaccination

Mali Rolls Out Cancer-Blocking Jab

“In a historic move, the government of Mali has introduced the human papillomavirus (HPV) vaccine into its routine immunisation programme. During a ceremony held in Bamako earlier this month, and attended by numerous dignitaries and international partners, Gavi and the Ministry of Health and Social Development emphasised the importance of this initiative, terming it a significant step forward in preventing cervical cancer among Malian women.”

From Gavi.

World Health Organization | Vaccination

Cross-Border Polio Vaccination Reaches 6.5 Million Children

“Between October 3 and 6, 2024, more than 6.5 million children were vaccinated in a successful synchronized polio campaign between Kenya and Uganda. This cross-border achievement began with a coordinated launch in Bungoma District, Kenya, and Mbale District, Uganda. 

Both countries have set an exemplary standard in their recent synchronized polio vaccination campaign conducted this week, which focused on high-risk cross-border regions. By conducting these campaigns on the same dates, sharing real-time information, both countries ensured that children under five in these vulnerable areas were reached effectively, reducing the chance of cross-border virus transmission.”

From World Health Organization.

The Guardian | Vaccination

Doctors Trial mRNA Vaccine Against Vomiting Bug Norovirus

“Doctors have begun trialling the world’s first mRNA vaccine against the vomiting bug norovirus in the hope the jab could bring huge health and economic benefits.

Norovirus causes sickness and diarrhoea and can spread very rapidly between people who are in close contact, with outbreaks often occurring in hospitals, care homes, schools and nurseries.

While most people recover within two to three days, the virus can be serious, particularly for the very young, elderly or people with a weakened immune system…

Called Nova 301, the phase 3 clinical trial is to run for two years, and will enrol 25,000 adults – with a focus on those over the age of 60 – from countries including Japan, Canada and Australia.”

From The Guardian.